APT Medical (688617) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached ¥1.53 billion, up 25.75% year-over-year, with net profit attributable to shareholders at ¥537 million, up 26.38%.

• Core business segments—electrophysiology and vascular intervention—drove growth, with significant market share gains domestically and internationally.

• R&D investment remained robust at ¥197 million, representing 12.89% of revenue.

• The company continued to expand its product portfolio, launch new products, and strengthen its competitive position.

Financial highlights

• Operating income: ¥1.53 billion, up 25.75% year-over-year.

• Net profit attributable to shareholders: ¥537 million, up 26.38% year-over-year.

• Operating cash flow: ¥549 million, up 23.53% year-over-year.

• Basic and diluted EPS: ¥3.82, up over 26% year-over-year.

• Gross margin: 73.0% (calculated from disclosed cost and revenue).

Outlook and guidance

• The company expects continued growth driven by product innovation, market expansion, and increased penetration in both domestic and international markets.

• Ongoing investments in R&D and manufacturing capacity are expected to support future product launches and market share gains.